Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1137-1145

  Waters, E K ^a,b   Genga, R M ^a,b,d   Thomson, H A ^b,e   Kurz, J C ^a,b   Schaub, R G ^b,f   Scheiflinger, F ^c   Mcginness, K E ^a,g  

^a Baxter Healthcare Corporation   (United States)

^b Archemix Corporation   (United States)

^c BAXTER INNOVATIONS GMBH   (Austria)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e X Chem Incorporated   (United States)

^f NKT Therapeutics   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Aptamer; BAX 499; Hemophilia; Tissue factor pathway inhibitor

Indexed keywords

APTAMER; BAX 499 APTAMER; BLOOD CLOTTING FACTOR 7; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; IN VITRO STUDY; MASS SPECTROMETRY; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION;

APTAMER; BAX 499; HEMOPHILIA; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIBODIES; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; COAGULANTS; DEUTERIUM EXCHANGE MEASUREMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; HEMOPHILIA A; HUMANS; HYDROGEN; INHIBITORY CONCENTRATION 50; LIPOPROTEINS; PEPTIDES; PROTEIN BINDING; PROTEIN S; PROTEIN STRUCTURE, TERTIARY; THROMBOPLASTIN;

EID: 84883756006     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12201     Document Type: Article

References (36)

1. Crawley JTB, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28: 233-42.
2. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012; 17: 262-80.
3. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
4. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
5. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
6. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-9.
7. Petersen LC, Bjørn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 1996; 235: 310-16.
8. Peraramelli S, Suylen DP, Rosing J, Hackeng TM. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Thromb Haemost 2012; 108: 266-76.
9. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-α is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116: 1344-51.
10. Ahnström J, Andersson HM, Hockey V, Meng Y, McKinnon TA, Hamuro T, Crawley JT, Lane DA. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 2012; 120: 5059-62.
11. Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-11.
12. Ndonwi M, Broze G Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 6: 1044-6.
13. Norfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-7.
14. Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res 1991; 64: 213-22.
15. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6: 388-94.
16. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-22.
17. Parunov LA, Fadeeva OA, Balandina AN, Soshitova NP, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011; 9: 1825-34.
18. Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, Knoebl P, Gilbert JC, Schaub RG, Dockal M, McGinness KE, Pabinger I, Srivastava A. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost 2012; 10: 1581-90.
19. Chang JY, Chantrathammachart P, Monroe DM, Key NS. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res 2012; 130: e151-7.
20. Gissel M, Orfeo T, Foley JH, Butenas S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 2012; 130: 948-55.
21. Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, Johnson KW. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
22. Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, Powell S, Johnson KW. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008; 111: 672-9.
23. Dockal M, Thomassen MCLGD, Heinzmann ACA, Duckers C, Hartmann R, Scheiflinger F, Rosing J. Inhibition of tissue factor pathway inhibitor (TFPI) by small peptides protects FXa and enhances FXa and thrombin formation in model systems and in plasma. J Thromb Haemost 2011; 9: 46-7. (ISTH abstract O-MO-112)
24. Dockal M, Fries M, Brandstetter J, Ludwiczek M, Kontaxis G, Prohaska K, Hofbauer A, Kammlander W, Hartmann R, Ehrlich H, Scheiflinger F. Peptides binding to kunitz domain 1 of tissue factor pathway inhibitor inhibit the interaction with factor Xa. J Thromb Haemost 2011; 9: 29-30. (ISTH abstract O-MO-057)
25. Dockal M, Hartmann R, Polakowski T, Osterkamp F, Kammlander W, Panholzer E, Kolm A, Redl C, Ehrllich H, Scheiflinger F. Improvement of hemostasis in hemophilia by peptides inhibiting tissue factor pathway inhibitor. J Thromb Haemost 2011; 9: 349. (ISTH abstract P-TU-129)
26. Dockal M, Pachlinger R, Baldin-Stoyanova A, Knofl F, Hartmann R, Backovic A, Ehrlich H, Scheiflinger F. Inhibition of cell-associated tissue factor pathway inhibitor (TFPI) increases factor VIIA-TF dependent factor X activation. J Thromb Haemost 2011; 9: 348. (ISTH abstract P-TU-128)
27. Hoellriegl W, Dockal M, Schiviz A, Lawo JP, Verdino D, Leidenmuehler P, Schwarz H-P, Ehrlich H, Hartmann R, Muchitsch E-M, Scheiflinger F. Inhibition of TFPI efficiently improves hemostasis in hemophilc mice. J Thromb Haemost 2011; 9: 559. (ISTH abstract P-WE-126)
28. Hilden I, Lauritzen B, Sørensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjørn SE. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871-8.
29. Knappe S, Kripalani N, Patarroyo-White S, Johnson KW, Prasad S. AV513 enhances tissue factor activity by inhibiting TFPI in hemophilia A plasma: potential TFPI target sites and potentiation of factor VIII activity. Blood 2007; 110: 497. (ASH Annual Meeting Abstracts)
30. Palige M, Redl C, Knappe S, Ehrlich HJ, Dockal M, Scheiflinger F. Procoagulant activity of Laminaria japonica derived fucoidan (BAX513) depends on the interaction with the C-terminus of tissue factor pathway inhibitor. Blood 2010; 116: 4417. (ASH Annual Meeting Abstracts)
31. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-93.
32. Wong I, Lohman TM. A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc Natl Acad Sci USA 1993; 90: 5428-32.
33. Coales SJ, Tuske SJ, Tomasso JC, Hamuro Y. Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatograph and mass spectrometry. Rapid Commun Mass Spectrom 2009; 23: 639-47.
34. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-5.
35. Bai Y, Milne JS, Mayne L, Englander SW. Primary structure effects on peptide group hydrogen exchange. Proteins 1993; 17: 75-86.
36. Girard TJ, Tuley E, Broze GJ Jr. TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood 2012; 119: 1256-62.